Overexpression of miR-27a predicts poor prognosis and promotes the progression in cholangiocarcinoma
- PMID: 32816152
- DOI: 10.1007/s10238-020-00655-y
Overexpression of miR-27a predicts poor prognosis and promotes the progression in cholangiocarcinoma
Abstract
The function of microRNA-27a (miR-27a) expression in cholangiocarcinoma (CCA) remains largely unclear; therefore, this study aimed to investigate the clinical significance and functional role of miR-27a in CCA. This study included 117 paired CCA tissues and adjacent normal tissues from CCA patients who received surgical resection. Reverse transcription-quantitative polymerase chain reaction was used to measure the expression levels of miR-27a in CCA tissues and cell lines. A Kaplan-Meier curve and Cox regression analysis were used to determine overall prognostic performance. The effects of miR-27a on cell proliferation, migration, and invasion were measured by CCK-8 and Transwell assays. The expression levels of miR-27a in patients with CCA and cell lines were higher than those in adjacent normal tissues and normal cells, respectively. Additionally, miR-27a levels were found to be associated with lymph node metastasis and TNM stages. The overall survival time of CCA patients with high miR-27a expression was poorer than that of those with low miR-27a expression. Furthermore, miR-27a overexpression promoted CCA cell proliferation, migration, and invasion, whereas knockdown of miR-27a suppressed cell proliferation, migration, and invasion. Taken together, these results suggest the potential usefulness of miR-27a in the prognosis and progression of CCA.
Keywords: Cholangiocarcinoma; Invasion; MicroRNA-27a; Migration; Prognosis; Proliferation.
Similar articles
-
miR-378 serves as a prognostic biomarker in cholangiocarcinoma and promotes tumor proliferation, migration, and invasion.Cancer Biomark. 2019;24(2):173-181. doi: 10.3233/CBM-181980. Cancer Biomark. 2019. PMID: 30594918
-
Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.Tumour Biol. 2016 Nov;37(11):15019-15029. doi: 10.1007/s13277-016-5313-6. Epub 2016 Sep 22. Tumour Biol. 2016. PMID: 27658773
-
LINC00844 suppresses tumor progression and predicts survival outcomes through inhibiting miR-19a-5p in cholangiocarcinoma.Clin Transl Oncol. 2024 Feb;26(2):414-423. doi: 10.1007/s12094-023-03254-x. Epub 2023 Jul 3. Clin Transl Oncol. 2024. PMID: 37400667
-
miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma.Pharmacogenomics. 2017 Sep;18(14):1343-1358. doi: 10.2217/pgs-2017-0010. Epub 2017 Aug 23. Pharmacogenomics. 2017. PMID: 28832247 Review.
-
The Role of microRNAs in Cholangiocarcinoma.Int J Mol Sci. 2021 Jul 16;22(14):7627. doi: 10.3390/ijms22147627. Int J Mol Sci. 2021. PMID: 34299246 Free PMC article. Review.
Cited by
-
Tumor Microenvironment Remodeling in Gastrointestinal Cancer: Role of miRNAs as Biomarkers of Tumor Invasion.Biomedicines. 2023 Jun 19;11(6):1761. doi: 10.3390/biomedicines11061761. Biomedicines. 2023. PMID: 37371856 Free PMC article. Review.
References
-
- Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168–79. - DOI
-
- Blechacz B. Cholangiocarcinoma: current knowledge and new developments. Gut Liver. 2017;11(1):13–26. - DOI
-
- Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008;48(1):308–21. - DOI
-
- Squadroni M, Tondulli L, Gatta G, Mosconi S, Beretta G, Labianca R. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2017;116:11–31. - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical